<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01329744</url>
  </required_header>
  <id_info>
    <org_study_id>1K23DK080644-01A1</org_study_id>
    <nct_id>NCT01329744</nct_id>
  </id_info>
  <brief_title>Effects of IGF-I in HIV Metabolic Disease</brief_title>
  <official_title>Effects of Recombinant IGF-I in HIV Associated Metabolic Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study examines the effects of recombinant insulin like growth factor - I on body
      composition, glucose homeostasis, and lipids, in adults with HIV infection and signs of
      metabolic disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objectives of this study are the following:

        1. Determine the effect of recombinant human insulin like growth factor-I (rhIGF-I)
           (generic: mecasermin) on subcutaneous adiposity in patients with HIV lipodystrophy
           syndrome.

        2. Determine the effects of rhIGF-I on glucose homeostasis and lipids in patients with HIV
           lipodystrophy.

        3. Determine the effects of rhIGF-I on apoptosis, mitochondria, and inflammation, in
           adipose tissue obtained from patients with HIV lipodystrophy.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Body composition</measure>
    <time_frame>24 weeks</time_frame>
    <description>Participants will have a body scan called a dual energy x-ray absorptiometry (DEXA) scan and a single slice abdominal CT scan and mid thigh scan to measure subcutaneous and internal fat.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucose Homeostasis</measure>
    <time_frame>24 weeks</time_frame>
    <description>Fasting glucose and insulin will be measured. A subset of patients will undergo a hyperinsulinemic clamp.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>HIV Lipodystrophy</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recombinant IGF-I</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mecasermin</intervention_name>
    <description>a subcutaneous injection twice a day</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Increlex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo control</intervention_name>
    <description>Subcutaneous injection given twice per day of placebo compound, for 24 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV positive with undetectable viral load

          -  No change in antiretrovirals for 3 months

          -  Evidence of lipoatrophy in the limbs, and face or gluteal area

          -  Dyslipidemia defined as:

          -  Fasting triglycerides &gt; 200 OR

          -  HDL cholesterol &lt; 40 mg/dL

          -  Abnormal glucose homeostasis defined as:

          -  Fasting hyperinsulinemia &gt; 20 uU/mL OR

          -  Fasting glucose 100-125 mg/dL, inclusive

        Exclusion Criteria:

          -  Two consecutive viral &gt;75 or &gt; 50 copies/mL using the tests listed above

          -  Presence of AIDS wasting

          -  Change in antiretroviral medication (not dose) in the prior 3 months

          -  Coronary artery disease, cerebrovascular, or peripheral arterial disease

          -  Diabetes mellitus

          -  Adrenal insufficiency, hypoglycemia, thyroid disease, or other endocrine disorder that
             is untreated

          -  Malignancy

          -  Eating disorder

          -  Pregnancy (urine pregnancy test is required of all females)

          -  Previous liposuction or bariatric surgery

          -  Other systemic conditions or other disorders at the discretion of the investigators

          -  Current use of systemic glucocorticoids, or other agent affecting body weight or
             glucose homeostasis or other drug at the discretion of the investigators

          -  Use of interferon within the past six months

          -  Use of insulin, insulin secretagogue, thiazolidinedione, or metformin in the prior 3
             months

          -  Initiation or dose adjustment, within the prior 3 months, of any of the following
             drugs or drug classes: fibrate, cholesterol binding resin, statin, niacin, or omega 3
             fatty acid (fish oil).

          -  Use of uridine, growth hormone, IGF-I, and growth hormone releasing factor analogues
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roy J Kim, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Southwestern Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2011</study_first_submitted>
  <study_first_submitted_qc>April 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2011</study_first_posted>
  <last_update_submitted>March 22, 2016</last_update_submitted>
  <last_update_submitted_qc>March 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Roy Kim</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>HIV lipodystrophy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Lipodystrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mecasermin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

